MARLBOROUGH, Mass., Nov. 8, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its HeartLight EAS will be discussed as a state-of-the-art technology and featured in a patient case presentation at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, November 7-11, San Francisco, CA.
TCT is the world's largest educational conference for interventional cardiovascular medicine. The HeartLight EAS technology will be presented Thursday, November 10 during the first ever Electrophysiologic Intervention Twilight Symposium, organized in partnership with PCI Live. Prof. Thorsten Lewalter, MD, of Isar Heart Center Munich, Germany, will present a prerecorded patient case with the HeartLight EAS technology titled, "Laser Balloon Ablation for Treatment of Atrial Fibrillation," at 7:30 p.m. local time.
"The addition of electrophysiology to the TCT program this year is an important development for the treatment of cardiac arrhythmias, and provides an opportunity to share advances in catheter-based ablation procedures with the interventional cardiology community. Research has shown that arrhythmias such as atrial fibrillation can change the structure of the heart, so achieving an effective, durable treatment is a common goal among these specialties. The visually-guided HeartLight EAS represents a major advance in treatment options and I am looking forward to sharing the technology with my peers at the meeting," said Prof. Lewalter.
"TCT is one of the most important conferences for interventional cardiologists, and we are excited that HeartLight EAS will be at the center of this significant discussion among physician thought leaders," said Stephen Sagon, President and CEO of CardioFocus. "We look forward to continued collaboration between these cardiology specialties, leading to further innovation in arrhythmia care."
HeartLight EAS incorporates an endoscope for direct visualization and a compliant, dynamically adjustable balloon catheter designed for improved contact with the PV ostium irrespective of the individual patient anatomy. It also utilizes laser energy for more efficient, durable and precise ablation treatment. The technology has been used to successfully treat more than 400 patients with AF in the United States and in Europe
For more information about the HeartLight EAS or CardioFocus, please visit www.CardioFocus.com.
About CardioFocus, Inc.
CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight™ Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.
The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe. The device is investigational in the U.S., with a pivotal study expected to commence in 2011. CardioFocus is headquartered in Marlborough, MA, USA. For more information on the company and its technology, please visit www.CardioFocus.com.
The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.
SOURCE CardioFocus, Inc.